 |
Top 18 Pulmonology startups
Oct 10, 2024 | By Jason Kwon | 30 |
These startups develop new technologies to diagnose and treat pulmonary disorders, such as wearable sensors, telemedicine platforms, AI-driven diagnostic tools, remote patient monitoring, plethysmography, wearable lung function monitors, high-resolution computed tomography.
1
Country: New Zealand | Funding: $15.4M
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
2
Country: USA | Funding: $295.5M
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
3
Country: UK | Funding: $205.5M
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
4
Country: USA | Funding: $140.4M
Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.
Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.
5
Country: UK
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
6
Country: UK | Funding: £68.8M
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
7
Country: USA | Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
8
Country: USA | Funding: $41M
We create breath-based diagnostic and monitoring devices with the aim to improve the lives of those with respiratory conditions like asthma, COPD, cystic fibrosis and pulmonary hypertension.
We create breath-based diagnostic and monitoring devices with the aim to improve the lives of those with respiratory conditions like asthma, COPD, cystic fibrosis and pulmonary hypertension.
9
Country: Denmark | Funding: $27M
In many conventional hygiene products found traces of synthetic fabrics such as bleach, chemical residues, perfume, cellulose, plastic,
In many conventional hygiene products found traces of synthetic fabrics such as bleach, chemical residues, perfume, cellulose, plastic,
10
Country: USA | Funding: $23.3M
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
